Literature DB >> 25153535

Oxytocin and social cognition in affective and psychotic disorders.

M Mercedes Perez-Rodriguez1, Katie Mahon2, Manuela Russo2, Allison K Ungar2, Katherine E Burdick2.   

Abstract

Impairments in social cognition are now recognized as core illness features in psychotic and affective disorders. Despite the significant disability caused by social cognitive abnormalities, treatments for this symptom dimension are lacking. Here, we describe the evidence demonstrating abnormalities in social cognition in schizophrenia, major depressive disorder, and bipolar disorder, as well as the neurobiology of social cognition including the role of oxytocin. We then review clinical trials of oxytocin administration in psychotic and affective disorders and the impact of this agent on social cognition. To date, several studies have demonstrated that oxytocin may improve social cognition in schizophrenia; too few studies have been conducted in affective disorders to determine the effect of oxytocin on social cognition in these disorders. Future work is needed to clarify which aspects of social cognition may be improved with oxytocin treatment in psychotic and affective disorders.
Copyright © 2014 Elsevier B.V. and ECNP. All rights reserved.

Entities:  

Keywords:  Bipolar disorder; Major depressive disorder; Oxytocin; Schizophrenia; Social cognition

Mesh:

Substances:

Year:  2014        PMID: 25153535      PMCID: PMC4443696          DOI: 10.1016/j.euroneuro.2014.07.012

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  178 in total

Review 1.  Persecutory delusions: a review and theoretical integration.

Authors:  R P Bentall; R Corcoran; R Howard; N Blackwood; P Kinderman
Journal:  Clin Psychol Rev       Date:  2001-11

2.  Theory of Mind and psychometric schizotypy.

Authors:  Diane Carol Gooding; Madeline Johnson Pflum
Journal:  Psychiatry Res       Date:  2011-05-19       Impact factor: 3.222

3.  The relation of empathy to prosocial and related behaviors.

Authors:  N Eisenberg; P A Miller
Journal:  Psychol Bull       Date:  1987-01       Impact factor: 17.737

Review 4.  Identification of separable cognitive factors in schizophrenia.

Authors:  Keith H Nuechterlein; Deanna M Barch; James M Gold; Terry E Goldberg; Michael F Green; Robert K Heaton
Journal:  Schizophr Res       Date:  2004-12-15       Impact factor: 4.939

5.  Investigating theory of mind in schizophrenia: influence of verbalization in disorganized and non-disorganized patients.

Authors:  Y Sarfati; M C Hardy-Baylé; E Brunet; D Widlöcher
Journal:  Schizophr Res       Date:  1999-05-25       Impact factor: 4.939

6.  Effects of single dose intranasal oxytocin on social cognition in schizophrenia.

Authors:  Michael C Davis; Junghee Lee; William P Horan; Angelika D Clarke; Mark R McGee; Michael F Green; Stephen R Marder
Journal:  Schizophr Res       Date:  2013-05-12       Impact factor: 4.939

7.  Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders.

Authors:  Abraham Reichenberg; Philip D Harvey; Christopher R Bowie; Ramin Mojtabai; Jonathan Rabinowitz; Robert K Heaton; Evelyn Bromet
Journal:  Schizophr Bull       Date:  2008-05-20       Impact factor: 9.306

8.  Theory of mind disability in major depression with or without psychotic symptoms: a componential view.

Authors:  Yong-Guang Wang; Yi-Qiang Wang; Shu-Lin Chen; Chun-Yan Zhu; Kai Wang
Journal:  Psychiatry Res       Date:  2008-10-16       Impact factor: 3.222

9.  Oxytocin enhances social persuasion during hypnosis.

Authors:  Richard A Bryant; Lynette Hung
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

Review 10.  Social cognition.

Authors:  Chris D Frith
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2008-06-12       Impact factor: 6.237

View more
  8 in total

1.  First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma.

Authors:  Anika Hoffmann; Jale Özyurt; Kristin Lohle; Julia Reichel; Christiane M Thiel; Hermann L Müller
Journal:  Endocrine       Date:  2017-02-17       Impact factor: 3.633

Review 2.  Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.

Authors:  Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-06       Impact factor: 3.568

3.  Distinct oxytocin effects on belief updating in response to desirable and undesirable feedback.

Authors:  Yina Ma; Shiyi Li; Chenbo Wang; Yi Liu; Wenxin Li; Xinyuan Yan; Qiang Chen; Shihui Han
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

4.  The relationship between sleep quality and neurocognition in bipolar disorder.

Authors:  Manuela Russo; Katie Mahon; Megan Shanahan; Elizabeth Ramjas; Carly Solon; Shaun M Purcell; Katherine E Burdick
Journal:  J Affect Disord       Date:  2015-08-28       Impact factor: 4.839

5.  Effects of oxytocin on empathy, introspective accuracy, and social symptoms in schizophrenia: A 12-week twice-daily randomized controlled trial.

Authors:  Tate Halverson; L Fredrik Jarskog; Cort Pedersen; David Penn
Journal:  Schizophr Res       Date:  2018-09-20       Impact factor: 4.939

6.  The Role of Intranasal Oxytocin on Social Cognition: An Integrative Human Lifespan Approach.

Authors:  Marilyn Horta; Didem Pehlivanoglu; Natalie C Ebner
Journal:  Curr Behav Neurosci Rep       Date:  2020-09-12

7.  Neuroenhancement of Exposure Therapy in Anxiety Disorders.

Authors:  Stefan G Hofmann; Elizabeth A Mundy; Joshua Curtiss
Journal:  AIMS Neurosci       Date:  2015

8.  A Role for the Transcription Factor Nk2 Homeobox 1 in Schizophrenia: Convergent Evidence from Animal and Human Studies.

Authors:  Eva A Malt; Katalin Juhasz; Ulrik F Malt; Thomas Naumann
Journal:  Front Behav Neurosci       Date:  2016-03-30       Impact factor: 3.558

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.